Somatic POLE mutation and ultra-hypermutated genotype in a de novo high-grade, isocitrate dehydrogenase wild-type glioma: Treatment implications

Authors

Daniel Mundt, Advocate Aurora HealthFollow
Isaac Melguizo-Gavilanes, Advocate Aurora HealthFollow
Anil Y. Tumu, Advocate Aurora HealthFollow
Steven Dubner, Advocate Aurora HealthFollow
Mary K. Walters, Advocate Aurora HealthFollow
Laura McFarlane, Advocate Aurora HealthFollow

Recommended Citation

Mundt D, Melguizo-Gavilanes I, Tumu AY, Dubner S, Walters MK, McFarlane L. Somatic POLE Mutation and Ultra-Hypermutated Genotype in a De Novo High-Grade, Isocitrate Dehydrogenase Wild-Type Glioma: Treatment Implications. JCO Precis Oncol. 2024;8:e2300324. doi:10.1200/PO.23.00324

Abstract

Pembrolizumab leads to a durable response in ultra-hypermutated, high-grade, glioma.

Type

Article

PubMed ID

38237101